Puma Biotechnology Inc

Puma Biotechnology Inc. is a company based in Los Angeles, California. With 256 employees, Puma Biotechnology operates in the United States. Puma Biotechnology focuses on developing innovative therapies for cancer patients, particularly those with HER2+ breast cancer. Their mission is to enhance cancer care by providing new treatment options across the spectrum of breast cancer therapy. Puma Biotechnology is dedicated to evaluating and advancing therapies that may benefit patients within the HER2+ breast cancer community. For more information about Puma Biotechnology and their therapies, please visit pumabiotechnology.com.

Puma Biotechnology, Inc. is a biopharmaceutical company. It focuses on the acquisition, development, and commercialization of novel therapeutics for cancer treatment. The company is located in Los Angeles, California, with its main address at 10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA 90024. Puma Biotechnology operates within the healthcare, pharmaceuticals, and biotechnology industries. The company's operations include conducting clinical trials and offering FDA-approved treatments. The company's focus is on developing innovative drug candidates. The company's offerings include therapeutics for cancer treatment. Puma Biotechnology provides FDA-approved treatments. The company's contact information includes multiple email addresses, such as [email protected], [email protected], [email protected], [email protected], [email protected], [email protected], and [email protected]. The company can also be reached by phone at 424-248-6500 or 1-844-633-7862. Puma Biotechnology targets the healthcare, pharmaceutical, and biotechnology industries. The company's competitive advantages include a focus on innovative drug candidates and FDA-approved treatments. The company has a strong leadership team. Puma Biotechnology is committed to patient care, innovation in drug development, and corporate governance and ethics. The company's leadership team includes Alan H. Auerbach as Chief Executive Officer, President, and Chairman of the Board; Maximo F. Nougues as Chief Financial Officer; and Douglas Hunt, B.Sc (Hons). as Chief Regulatory Affairs, Medical Affairs, and Pharmacovigilance Officer.